



Access to medicines at EB146

Natalie Rhodes
People's Health Movement / UAEM Europe



50 resolutions
45 regional consultations
67 technical documents

Directly or indirectly related to access to medicines from 2007 - 2017



ROAD MAP FOR ACCESS TO MEDICINES, VACCINES AND
OTHER HEALTH PRODUCTS, 2019–2023

What's on at EB146?

- Item 8: Global Vaccine Action Plan (GVAP)
- Item 9: Accelerating the elimination of cervical cancer as a global public health problem
- Item 10: Ending tuberculosis (R&D strategy)
- Item 13: Neglected tropical diseases
- Item 14: Global strategy and plan of action (GSPOA) on public health, innovation and intellectual property

The GSPOA was adopted in 2008 to *promote new thinking on innovation and access to medicines and to secure an enhanced and sustainable basis for needs driven essential health research and development relevant to diseases that disproportionately affect developing countries*

	TRIPs	1995
MS agreed to establish investigative body		2003
Intergovernmental working group POA		2006
Consultative Experts Working Group R&D treaty		2011
Proposed 108 -> 33 action points		2017
Brazil requested GSPOA be discussed at EB146		2019

2001	Doha declaration (TRIPs flexibilities)
2004	Commission on Intellectual Property Rights, Innovation and Public Health
2008	GSPOA adopted
2015	GSPOA extension Resolution on transparency
2018	EB noted the review (with some contention)

How EB 142 started (9th Jan)

(1) to take forward the recommendations of the review panel following the drawing up of a detailed implementation plan, in accordance with the review panel's recommendations;

How EB 142 ended (26th Jan)

(1) to urge Member States to **implement, as appropriate** and taking into account national contexts, the recommendations of the review panel that are addressed to Member States and **consistent with** the global strategy and plan of action on public health, innovation and intellectual property;

(2) to urge Member States to **further discuss** the recommendations of the review panel **not emanating** from the global strategy and plan of action on public health, innovation and intellectual property;

(3) to request the Director-General to implement the recommendations addressed to the Secretariat as prioritized by the review panel, in an implementation plan, consistent with the global strategy and plan of action on public health, innovation and intellectual property;

2018 EB - what changed?

33 action points for
Secretariat AND
Member States



22 action points only
for Secretariat

No...Transparency,
shortages, funding

Recommendations “not emanating” from GSPOA

4. Transparency of R&D costs

27. Medicine shortages

28. 0.01% of GDP for R&D relevant to developing countries